



Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara@gmail.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/11/23

November 8, 2023

To,
The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016
Segment : SME

Dear Sir/Madam,

Sub: Outcome of Board meeting held on today i.e. on November 08, 2023, in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Unaudited Financial Results for the half year ended on September 30, 2023 and Limited Review Report of the Statutory Auditors thereon.

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at their Board Meeting held on today, i.e. on Wednesday, November 08, 2023, at the Registered Office of the Company situated at "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India and which was commenced at 5.30 p.m. & concluded at 6.10 p.m. has inter-alia considered and approved the following:

1. Considered, approved and taken on record the Standalone Unaudited Financial Results of the Company for the half year ended on September 30, 2023.
2. Limited Review Report issued by Statutory Auditors for the half year ended on September 30, 2023.
3. Considered and approved all other business as per agenda circulated.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Standalone Unaudited Financial Results for the half year ended on September 30, 2023 and Limited Review Report issued by Statutory Auditors for the half year ended on September 30, 2023.

Kindly take the above on record.

For AATMAJ HEALTHCARE LIMITED

SUVAGIYA
TUSHAR
KARSHANBHAI
Date: 2023.11.08
18:12:04 +05'30'

Tushar K Suvagiya
Managing Director
DIN: 06802410

Date: 08/11/2023
Place: Vadodara

Encl : As Above



Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara@gmail.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/11/23

November 8, 2023

To,
The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016
Segment : SME

Dear Sir/Madam,

Sub: Submission of Standalone Unaudited Financial Results for the Half year ended on September 30, 2023 and Limited Review Report of the Statutory Auditors thereon.

With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone Unaudited Financial Results of the Company for the half year ended September 30, 2023, along with Review Report for the half year ended September 30, 2023.

Kindly take the above on record.

For AATMAJ HEALTHCARE LIMITED

SUVAGIYA
TUSHAR
KARSHANBHAI
Digitally signed by
SUVAGIYA TUSHAR
KARSHANBHAI
Date: 2023.11.08
18:12:29 +05'30'

Tushar K Suvagiya
Managing Director
DIN: 06802410

Date: 08/11/2023
Place: Vadodara

Encl : As Above

Independent Auditor's Report on the unaudited standalone financial results of Aatmaj Healthcare Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Aatmaj Healthcare Limited
CIN: U85100GJ2014PLC079062
Vadodara

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Aatmaj Healthcare Limited** ("the Company"), for the half year ended September 30, 2023 ("the Statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement which is responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (As 25), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of listing regulations. Our responsibility is to issue a report on this Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform our review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personnel analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express and audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

For Bela Mehta and Associates
Chartered Accountants
FRN : 101073W


Shital S Parikh
M.No.: 121609
UDIN: 23121609BGUXCQ6166



Date: 08/11/2023
Place: Vadodara

Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,

Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,

Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

Statement of Unaudited Standalone Financial Results for the Half Year ended on 30.09.2023

(Rs. In Lakhs)

Particulars	Six Months Ended			For the year ended March 31, 2023 Audited
	30.09.2023 Unaudited	31.03.2023 Audited (Refer Note 3)	30.09.2022 Unaudited	
Revenue from operations	856.64	1,374.07	1,342.19	2,716.26
Other income	23.60	-	2.64	2.64
Total Revenue	880.24	1,374.07	1,344.83	2,718.90
Expenses				
Cost of Materials Consumed	71.73	56.16	118.00	174.16
Purchases of Stock-in-Trade	-	-	-	-
Changes in Inventories of Finished Goods, work-in-progress and Stock-in-Trade	-	-	-	-
Employee Benefits Expense	115.33	212.90	252.81	465.71
Finance costs	58.68	64.85	24.66	89.51
Depreciation and Amortization Expense	38.06	34.36	34.41	68.77
Other Expenses	282.11	580.16	513.23	1,093.39
Total Expenses	565.91	948.43	943.11	1,891.54
Profit Before Tax	314.33	425.64	401.72	827.36
Tax expense:				
Current tax	77.00	115.76	103.45	219.21
Deferred tax	8.72	9.38	8.12	17.50
Profit/(loss) for the period	228.61	300.50	290.15	590.65
Earnings per equity share:				
Basic	1.01	1.85	5.37	3.64
Diluted	1.01	1.85	5.37	3.64

On Behalf of the Board,
For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 08/11/2023
Place: Vadodara



Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568


Notes attached to Unaudited Standalone Financial Results for the Half Year ended September 30, 2023

1. The above standalone financial results of the company ("the statement") have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on November 9, 2023 and have been subjected to limited review by the statutory auditors of the company on which the auditors have been expressed an unmodified Opinion.
2. The Standalone Financial results has been prepared in accordance with recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (As 25) as prescribed under section 133 of the companies act, 2013 ("the Act") read with the companies (accounting standards) Rules, 2021, as amended from time to time and other accounting principal generally accepted in India.
3. The figures for the Half year ended March 31, 2023 are the balancing figures between audited figures in respect of year ended March 31, 2023 and figures for the half year ended September 30, 2022.
4. The company is engaged primarily in the business of Operating Multi Specialties Hospitals and all its operations are in India only. Accordingly, there is no separate reportable segment as per AS 17 on "Segment Reporting" in respect of Company.
5. The Company applied to National Stock Exchange of India Limited ("NSE") for in-principle approval for listing its equity shares on the Emerge Platform of the NSE. National Stock Exchange of India Limited has, vide its letter dated June 1, 2023 granted it's In Principle Approval to the Company. The Company had filed Prospectus to the Registrar of the Company, Ahmedabad on June 13, 2023. The Public Issue was opened on Monday, June 19, 2023 and closed on Wednesday, June 21, 2023. The Basis of Allotment was finalized by Company, Registrar to the issue and merchant banker in consultation with the NSE on June 26, 2023. The Company has applied for listing of its total equity shares to NSE and it has granted its approval vide its letter dated June 28, 2023. The trading of equity shares of the Company commenced w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE).

Sr. No.	Objects as per Prospectus	(Rs. In Lacs)		
		Allocation as per Prospectus	Fund utilised up to September 30, 2023	Balance as on September 30, 2023
1	Repayment/Prepayment in full or part of existing secured debt of the company	900.00	900.00	-
2	Funding the working capital requirements of the company	600.00	600.00	-
3	Purchase of medical equipment for hospitals of our company and/or newly acquired or set up hospitals	913.11	90.00	823.11
4	Our inorganic growth initiatives through acquisitions and other strategic initiatives	620.00	-	620
5	General Corporate Expenses	496.89	218.53	278.36
6	Issue Expenses	310.00	310.00	-
	Total Rs. In Lacs	3,840.00	2,118.53	1,721.47

6. Unaudited statements of Assets and liabilities and Statement of Cash Flow are attached as "Annexure A" and "Annexure B" respectively.
7. Previous year's/period's figures have been regrouped/reclassified whenever necessary.

On Behalf of the Board,
For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 08/11/2023
Place: Vadodara

Annexure A: Standalone Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	As at September 30, 2023	As at March 31, 2023
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share capital	1,130.00	810.00
Reserves and surplus	3,968.41	607.76
	5,098.41	1,417.76
Non-Current Liabilities		
Long-term borrowings	144.66	179.27
Deferred Tax Liabilities (Net)	75.88	67.17
Other Long-term liabilities	-	-
Long-term provisions	-	-
	220.54	246.44
Current Liabilities		
Short - Term Borrowings	915.35	990.55
Trade payables	16.95	211.95
Other Current Liabilities	5.91	8.98
Short - Term Provisions	87.26	225.02
	1,025.47	1,436.50
TOTAL	6,344.42	3,100.70
ASSETS		
Non-Current Assets		
Property, Plant and Equipment		
Tangible assets	1,169.67	1,113.30
Intangible assets	2.56	3.78
Capital work-in-progress	-	-
Intangible assets under development	-	-
	1,172.23	1,117.08
Non-current investments	-	-
Long-term loans and advances	-	-
Other non-current assets	-	-
	1,172.23	1,117.08
Current assets		
Inventories	49.73	40.05
Trade receivables	2,143.17	1,782.61
Cash and cash equivalents	1,936.08	31.68
Short-term loans and advances	1,019.73	108.51
Other current assets	23.48	20.77
	5,172.19	1,983.62
TOTAL	6,344.42	3,100.70

On Behalf of the Board,
For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 08/11/2023
Place: Vadodara



Aatmaj Healthcare Limited

(Formerly known as Aatmaj Healthcare Private Limited)

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,

Email: info@jupiterhospitalvadodara.com; CIN: U85100GJ2014PLC079062,


Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

ANNXURE B - STANDALONE CASH FLOW STATEMENT

(Rs. In Lakhs)

Particular	For the Half year ended September 30, 2023	For the year ended March 31, 2023
Cash Flows from Operating Activates		
Net Profit Before Tax and Extra Ordinary Items	314.33	827.36
Adjustment For		
Depreciation	38.06	68.77
Finance Cost	58.68	89.51
	411.07	985.64
Adjustment For working Capital Change		
(Increase)/Decrease in Inventories	(9.68)	0.45
(Increase)/Decrease in Trade Receivables	(360.56)	(1,273.00)
(Increase)/Decrease in Other Current Assets	(913.93)	(37.88)
Increase/(Decrease) in Trade Payable	(195.00)	48.18
Increase/(Decrease) in other current Liabilities	(3.07)	544.06
Increase/(Decrease) in Provisions	(137.76)	46.20
Total Adjustment For Working Capital	(1,620.00)	(671.99)
Net Cash flow from (Used in)/Generated from operation	(1,208.93)	313.65
Less: Income Tax Paid/ Refund	85.72	219.21
Net Cash flow From operating Activities	(1,294.65)	94.44
Cash Flows from Investing Activities		
Purchase of Fixed Assets	93.20	98.40
Purchase of Investments or Equity Instruments	-	(0.30)
Deposits Given	-	-
Net Cash flow Used in in Investing Activities	93.20	98.10
Cash Flows from Financial Activities		
Proceeds From Issuing Shares	3,452.04	-
Proceeds From Borrowing	-	(32.59)
Repayment of Borrowing	(212.32)	(344.96)
Increase/(Decrease) in short term Borrowings	(75.20)	288.14
Finance Cost	(58.68)	(89.51)
Net Cash flow from (Used in) in Financial Activities	3,105.84	(178.92)
Net increase (decrease) in cash and cash equivalents	1,904.39	13.62
Cash and cash equivalents at beginning of period	31.69	18.07
Cash and cash equivalents at end of period	1,936.08	31.69

On Behalf of the Board,
For Aatmaj Healthcare Limited


Tushar K Suvagiya
Managing Director
DIN: 06802410



Date: 08/11/2023
Place: Vadodara